AbbVie submits application to FDA for Tavapadon for treatment of Parkinson's disease
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
The submission is supported by positive results from the Phase 3 AMPLIFY trial
The submission is supported by results from the Phase 3b APEX study
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
It is intended for contrast enhancement in MRI scans
Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
Subscribe To Our Newsletter & Stay Updated